Mankind Pharma

Mankind Pharma

2,445.70
+7.60
(0.31%)
hide
Key Fundamentals
Add Ratio
Market Cap
1,00,634.60 Cr
EPS
49.28
PE Ratio
53.19
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
3,054.80
52 Week Low
2,115.10
PB Ratio
7.02
Debt to Equity
0.37
Analyst Rating and Forecast
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+62.50 %
+62.50 %
Hold
Hold+25.00 %
+25.00 %
Sell
Sell+12.50 %
+12.50 %
Forecast For
Actual

Company News

View All News
Caret
positive
Mankind Pharma has executed a business transfer agreement worth ₹797 crore with its wholly owned subsidiary Bharat Serums & Vaccines to acquire a women's health Rx branded generics portfolio.
neutral
Mankind Pharma executed a Business Transfer Agreement to acquire BSV's Women Health Rx Portfolio for ₹797 crore through a slump sale. The payment will be made in two installments: 50% on closing date and remaining within 150 days. In quarterly results, the company reported an 18.1% decline in net profit to ₹444.6 crore despite revenue surging 24.5% to ₹3,570 crore. EBITDA increased 26% to ₹847.6 crore with margin improving to 23.7%. Domestic revenue grew 18.9% to ₹3,101 crore while export revenue jumped 81.1% to ₹469 crore. Market share increased from 4.8% to 4.9% and secondary sales grew 9.2% compared to IPM's 8.6%. Shares closed down 0.62% at ₹2,464.
positive
Mankind Pharma has executed a Business Transfer Agreement worth ₹797 crore with Bharat Serums & Vaccines to acquire a Women's Health Rx branded generics portfolio. Bharat Serums & Vaccines is a wholly owned subsidiary of Mankind Pharma.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,655.10
#1 3,96,946.00
34.60
#1 54,729.00
9.71
#1 10,980
-19.84
55.91
6,573.00
1,74,173.90
75.51
9,712.00
18.67
2,191
26.74
71.24
1,558.70
1,25,387.70
23.26
28,409.50
7.12
5,291
9.88
56.22
3,532.80
1,19,200.50
58.98
11,539.40
6.99
1,911
19.91
45.41
1,232.40
1,03,266.80
#1 18.18
33,741.20
16.73
5,725
1.26
40.77
2,445.70
#6 1,00,634.60
#8 53.19
#8 12,744.20
#1 20.90
#9 2,007
#9 -18.14
40.52
977.30
98,535.50
21.13
23,511.00
18.55
4,615
2.60
40.14
1,940.50
88,487.10
23.92
22,909.50
13.74
3,306
#1 51.64
46.80
5,566.50
65,677.10
28.89
13,458.30
3.70
2,216
21.39
64.04
1,109.00
65,328.60
19.41
32,345.60
9.43
3,484
-10.24
53.54
Growth Rate
Revenue Growth
20.90 %
Net Income Growth
3.39 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
5.21 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,517
2,976
3,189
3,286
3,333
3,653
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,836
2,196
2,227
2,383
2,401
2,724
EBITDA
323
476
622
477
467
718
746
681
681
780
962
903
933
930
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
23 %
28 %
26 %
22 %
24 %
Depreciation
47
78
79
85
85
87
97
110
100
103
106
187
231
219
Interest
13
16
10
13
5
6
9
9
9
11
7
221
191
171
Profit Before Tax
263
382
533
379
377
625
641
562
572
666
849
495
511
541
Tax
70
84
110
83
84
130
130
103
95
123
190
111
86
96
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
425
445
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.46
10.19
10.62

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
6,373
9,148
9,715
11,963
27,760
Fixed Assets
1,664
3,588
4,251
4,545
19,005
Current Assets
3,907
4,407
4,328
6,568
6,988
Capital Work in Progress
372
702
550
282
826
Investments
1,512
1,110
1,346
2,568
2,042
Other Assets
2,824
3,749
3,568
4,568
5,887
Total Liabilities
6,373
9,148
9,715
11,963
27,760
Current Liabilities
1,353
2,624
1,863
2,120
5,664
Non Current Liabilities
156
208
229
268
7,528
Total Equity
4,863
6,316
7,623
9,576
14,568
Reserve & Surplus
4,682
6,115
7,395
9,323
14,291
Share Capital
40
40
40
40
41

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
103
-92
156
22
77
22
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
-12,624
Operating Activities
1,070
1,137
920
1,813
2,152
2,413
Financing Activities
-531
-8
605
-740
5
10,233

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
72.70 %
72.68 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
12.92 %
13.07 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
11.48 %
11.50 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
1.64 %
1.52 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
1.26 %
1.23 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431
1,80,597
1,79,549

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 2,114.50 2,068.60
05 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2024 2,506.95 2,734.95
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 2,738.25 2,515.05
21 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 May 2025 2,430.05 2,550.70
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jul 2025 2,578.00 2,575.00
07 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
07 Aug 2025 2,386.35 2,553.25
08 Aug 2025 DIVIDEND Dividend
₹ 1.00 /share
08 Aug 2025 2,575.00 2,541.90

Announcements

Announcement under Regulation 30 (LODR)-Updates on Acquisition5 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 04, 2025
Closure of Trading WindowSep 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Intimation Of Receipt Of Approval For ReclassificationSep 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Intimation Regarding ESG RatingAug 22, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Intimation For Submission Of Application For ReclassificationAug 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 01, 2025
Announcement Under Regulation 30- TDS Communication To The Shareholders.Jul 31, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 31, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Announcement under Regulation 30 (LODR)-RestructuringJul 31, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 31, 2025
Intimation Of Record DateJul 31, 2025
Corporate Action-Board approves DividendJul 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Un-Audited Financial Results For The Quarter Ended On June 30 2025Jul 31, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On July 31 2025Jul 31, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 24, 2025
Intimation Of Receipt Of Request For ReclassificationJul 22, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 18, 2025
Intimation Of Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company Or DepositoriesJul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 17, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 15, 2025
Reg. 34 (1) Annual Report.Jul 15, 2025
Notice Of 34Th Annual General Meeting Of Mankind Pharma LimitedJul 15, 2025
Closure of Trading WindowJul 14, 2025
Corporate Action-Board to consider DividendJul 14, 2025
Board Meeting Intimation for Unaudited Quarterly Financial Results & Interim DividendJul 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Intimation Of The Date Of 34Th Annual General Meeting (AGM) Of The CompanyJul 03, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 16, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 10, 2025
Intimation Under Regulations 30 & 51 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Environmental Social And Governance (ESG) RatingJun 04, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJun 02, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
HDFC Large Cap Fund Direct-Growth
1.50%
513094
0.29%
0.26%
Kotak Arbitrage Fund Direct-Growth
0.07%
-282375
-0.09%
0.07%
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth
0.37%
158036
0.16%
0.37%
Edelweiss Mid Cap Direct Plan-Growth
1.21%
130173
0.22%
0.71%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
2.95%
-120016
-0.56%
-0.93%
Edelweiss Focused Fund Direct - Growth
2.86%
116208
2.86%
2.86%
Canara Robeco Large and Mid Cap Fund Direct-Growth
0.08%
-109171
-0.11%
-0.15%
Edelweiss Business Cycle Fund Direct-Growth
2.41%
93155
1.31%
2.41%
Canara Robeco Mid Cap Fund Direct - Growth
1.38%
77000
0.42%
0.37%
Edelweiss Aggressive Hybrid Fund Direct - Growth
0.35%
45256
0.35%
0.35%
Tata Arbitrage Fund Direct - Growth
0.07%
45225
0.06%
0.07%
Bandhan Large & Mid Cap Fund Direct-Growth
0.99%
42131
0.03%
0.18%
Baroda BNP Paribas Health and Wellness Fund Direct-Growth
7.53%
40000
1.71%
2.02%
Mirae Asset Aggressive Hybrid Fund Direct-Growth
0.27%
-35000
-0.10%
0.27%
Axis Nifty Midcap 50 Index Fund Direct-Growth
1.42%
27794
1.42%
1.42%
Edelweiss Large Cap Fund Direct -Growth
0.47%
25858
0.47%
0.47%
Mirae Asset Small Cap Fund Direct-Growth
1.47%
25000
0.09%
-0.06%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
1.64%
22866
1.23%
1.31%
SBI Arbitrage Opportunities Fund Direct-Growth
0.02%
22050
0.01%
0.02%
Edelweiss Multi Cap Fund Direct - Growth
0.39%
20620
0.17%
0.39%
SBI Healthcare Opportunities Fund Direct Plan-Growth
3.34%
-20000
-0.15%
-0.23%
Bandhan Focused Fund Direct-Growth
2.23%
-19524
-0.35%
-0.37%
Canara Robeco Focused Fund Direct - Growth
2.49%
16000
0.09%
-0.01%
Invesco India Flexi Cap Fund Direct - Growth
1.37%
15233
-0.04%
-0.20%
Edelweiss Arbitrage Fund Direct-Growth
0.03%
-13725
-0.02%
0.03%

Technical Indicators

RSI(14)
Neutral
38.89
ATR(14)
Less Volatile
53.15
STOCH(9,6)
Neutral
49.15
STOCH RSI(14)
Neutral
36.16
MACD(12,26)
Bearish
-5.72
ADX(14)
Weak Trend
20.79
UO(9)
Bearish
53.02
ROC(12)
Downtrend And Accelerating
-3.49
WillR(14)
Neutral
-77.63

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years, 6 days)
Chairperson NameRAMESH CHAND JUNEJA